

2020

--	--	--	--

1

			002399SZ 09989HK
		21	21
	0755-26980311	0755-26980311	
	stock@hepalink.com	stock@hepalink.com	

2

	2,659,199,486.98	2,128,873,735.18	24.91%
	581,059,157.84	546,402,001.38	6.34%
	504,563,907.99	65,718,964.64	667.76%
	-245,548,153.21	-183,590,255.09	-33.75%
/	0.4659	0.4381	6.35%
/	0.4659	0.4381	6.35%

	7.70%	8.62%	-0.92%
	16,585,100,612.42	15,242,205,403.45	8.81%
	7,752,504,231.39	7,347,010,761.12	5.52%

3

		26,595		0	
10					
		38.01%	474,029,899	0	43,600,000
		32.72%	408,041,280	0	
		3.72%	46,425,600	0	
		3.23%	40,320,000	0	
		1.21%	15,118,035	0	
		0.87%	10,870,036	0	
		0.66%	8,258,825	0	
		0.57%	7,088,166	0	
		0.50%	6,247,987	0	

		0.32%	3,999,008	0	
		38.88%			

4

5

10

6

1

--	--	--	--	--	--	--

2016

16

112473


2016 11 08

--	--	--	--	--	--	--

2

	52.52%	50.98%	1.54%
EBITDA	7	7.62	-8.14%

1



2020
1.

2019

37.37%

24.07%

10.49

API

CGMP

1

IMS Health Analytics Link IMS AL) 2019
6.4%

2017 2017 2000 2019 8000
323 2019 669 8000
Prolongin (QCE)

2 API API 2018 API 50%
40.7% 2018 3.87
60%
2. CDMO 8.04 CDMO CDMO CDMO
CDMO 10.71% 2018 CDMO CDMO
SPL CDMO CDMO CDMO SPL
45 CDMO CMC CDMO
CDMO

3 CDMO III pDNA
pDNA Frost&Sullivan CDMO 24.9%
2018 15 2024 57 SPL

pDNA CDMO

CDMO 24.91%
667.76%

1.
2020 7 8 A+H
H 2020 7 31

2.

CHF RDX-208 2020 1 RDX-208 III MACE
 2 FDA FDA FDA FDA RDX-208 2020 6 RDX-208
 FDA FDA FDA FDA
 III NDA FDA FDA RDX-208 2020 6 RDX-208
 Oregovomab Resverlogix FDA
 Oregovomab CA125 OncoQuest
 38.74% II Oregovomab
 Oregovomab PFS 41.8 II PFS 12.2 (p=0.0027) OS(p=0.0043) PFS
 OncoQuest III FDA FDA EMA Oregovomab Oregovomab
 Oregovomab (poly ICLC/Hiltonol) II Oregovomab
 PD-1 PARP (niraparib) II Ib/IIa Oregovomab
 2 Kymab (IntelliSelect®) 8.6% Kymab
 Kymab KY1005 KY1005 IIa
 KY1005
 2
 1
 2020 1 1 " " 2017 7 5 14 --
 [2017]22
 2020 4 29
 2020 7 8 H
 " " 2020 < 21 -- > [2018]35
 2020 8 29
 2

